Cdc37 associates kinase clients to
Hsp90 and promotes the development
of cancers. Celastrol, a natural friedelane triterpenoid, can disrupt
the Hsp90–Cdc37 interaction to provide antitumor effects. In
this study, 31 new celastrol derivatives, 2a–2d, 3a–3g, and 4a–4t, were designed and synthesized, and their
Hsp90–Cdc37 disruption activities and antiproliferative activities
against cancer cells were evaluated. Among these compounds, 4f, with the highest tumor cell selectivity (15.4-fold), potent
Hsp90–Cdc37 disruption activity (IC50 = 1.9 μM),
and antiproliferative activity against MDA-MB-231 cells (IC50 = 0.2 μM), was selected as the lead compound. Further studies
demonstrated 4f has strong antitumor activities both
in vitro and in vivo through disrupting the Hsp90–Cdc37 interaction
and inhibiting angiogenesis. In addition, 4f exhibited
less toxicity than celastrol and showed a good pharmacokinetics profile
in vivo. These findings suggest that 4f may be a promising
candidate for development of new cancer therapies.